Immunomedics
IndustryBiotechnology
FoundedJuly 1982 (1982-07)
FounderDavid M. Goldenberg
DefunctOctober 23, 2020 (2020-10-23)
HeadquartersMorris Plains, New Jersey
ParentGilead Sciences
Websitewww.immunomedics.com Edit this on Wikidata

Immunomedics was a biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer. In 2020, the company was acquired by Gilead Sciences.[1]

History

Immunomedics was founded in July 1982 by David M. Goldenberg.[2]

Michael Pehl was named CEO in December 2017 but left due to personal reasons in February 2019.[3] At that time, Dr. Behzad Aghazadeh was named Executive Chairman.[4]

In October 2020, Gilead Sciences acquired the company.[1] In March 2022, Gilead announced the closing of the former Immunomedics facility in Morris Plains. [5]

Products

  • Epratuzumab is a humanized anti-CD22 monoclonal antibody in phase III trials for pediatric leukemia.
  • Sacituzumab govitecan (IMMU-132 / Trodelvy) is an anti-Trop-2-SN-38 antibody-drug conjugate for breast cancer and solid tumors. It was approved in April 2020 by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease.[6] In 2017, the company scrapped a licensing deal for the drug with Seagen that led to the resignation of founder David M. Goldenberg.[7]
  • Labetuzumab (IMMU-130) is an anti-CEACAM5-SN-38 antibody-drug conjugate in clinical trials for colorectal cancer.
  • Veltuzumab is an anti-CD20 monoclonal antibody for treatment of cancer.
  • Milatuzumab (IMMU-110) is an anti-CD74 monoclonal antibody for autoimmune diseases.
  • IMMU-114 is an anti-HLA-DR for hematological cancers.[8]

References

  1. 1 2 "Gilead Sciences Completes Acquisition of Immunomedics, Inc" (Press release). Business Wire. October 23, 2020.
  2. ↑ Feuerstein, Adam (January 25, 2017). "Immunomedics Sale Hinges on Proxy Battle Over Fate of Controversial Founder". TheStreet.com.
  3. ↑ Vinluan, Frank (February 28, 2019). "Immunomedics CEO Michael Pehl Resigns". Xconomy.
  4. ↑ "Immunomedics Form 8-K". U.S. Securities and Exchange Commission. February 22, 2019.
  5. ↑ "Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters". 8 March 2022.
  6. ↑ "FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments" (Press release). Food and Drug Administration. April 22, 2020.
  7. ↑ LEE, ARMIE MARGARET (May 5, 2017). "Immunomedics, Seattle Genetics Scrap License Deal". TheStreet.com.
  8. ↑ Chen, X; Chang, C-H; Stein, R; Goldenberg, D M (October 24, 2011). "The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD". Nature. 47 (7): 967–980. doi:10.1038/bmt.2011.203. PMID 22020022. S2CID 8988947.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.